Advancing
brain health throughout the female reproductive life cycle
Developing RNA therapeutics for reproductive-stage neurological disorders, beginning with postpartum depression.
Why
Postpartum depression affects around one in six women, yet its underlying biology remains poorly understood. PAM Life Sciences is building a new therapeutic path from molecular discovery.
01 / The scale of the gap
The cost of not knowing vs. the cost of finding out
One annual UK cohort carries a societal cost measured in billions. A decade of targeted biology funding is measured in millions.
Long-term societal cost of perinatal depression, anxiety and psychosis for one UK birth cohort; 72% is borne by the child.
Estimated NIH funding directed at underlying PPD physiology and pathobiology across the last decade.
02 / What the comparison reveals
This isn’t the cost of biology research. It’s the cost of PPD’s biology going unfunded.
Same ten-year window. Same funder. A like-for-like view of two underfunded areas of women’s health research.
NIH funding for polycystic ovary syndrome biology research across ten years.
NIH funding for PPD physiology and pathobiology over the same period.
03 / The field, unmasked
A field that looks bigger on paper than it is in practice
Published papers and named authors create a wide outer ring. The durable experimental core is much smaller.
Ten years of “PPD biology” studies
Structured PubMed screen across the past decade.
original studies genuinely investigating PPD biology
proposed or tested a genuinely new mechanism or target
paired it with meaningful human or translational validation
The “research community,” unmasked
Named authors across those same papers.
named authors on the decade’s PPD-biology papers
published more than one relevant paper
recurring senior authors anchoring the whole field
Biology
Understanding what changes in the postpartum brain
Pregnancy and childbirth require profound neurohormonal and synaptic adaptation. PAM Life Sciences is investigating whether a specific long non-coding RNA helps regulate this plasticity — and whether modulating that pathway could support healthier adaptation.
This is a preclinical hypothesis under investigation
Thesis
A new target in neurohormonal plasticity
PAM Life Sciences is investigating a previously unrecognised lncRNA regulator of postpartum neurological plasticity — target-led discovery looking at cause, not symptom, in a field that has almost none of it.
Team
SCIENTIFIC EXECUTION
Oxford DPhil Contributors
Four researchers contributing across experimental design, neurobiology, RNA biology and translational modelling
SCIENTIFIC ADVISORY BOARD — INFORMATION
PERINATAL PSYCHIATRY
RNA THERAPEUTICS
lncRNA & EPIGENETICS
PSYCHIATRIC CLINICAL TRIALS
TRANSLATIONAL NEUROSCIENCE
BIOTECH / PHARMA R&D
